Investigating BB-1701: Targeting HER2+ and HER2-low Metastatic Breast Cancer with ADC Therapy
Join Dr. Kelly E. McCann as she discusses her poster “An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).” Dr. McCann will dive into her exciting new phase 2 study evaluating BB-1701, a novel antibody drug conjugate for patients with HER2-positive and HER2-low metastatic breast cancer that have progressed on Enhertu, also known as trastuzumab deruxtecan (T-DXd). While the trial is still in its early stages, Dr. McCann will discuss the importance of ADCs in cancer treatment as well as the safety and efficacy of BB-1701, offering insights into its use in patients who are heavily pretreated. This session provides a unique opportunity to explore the treatment’s implications and connect with others in the cancer research community.
Speaker
-
Kelly McCann, M.D., Ph.D.Assistant Clinical Professor David Geffen School of Medicine UCLA Hematology and OncologyDr. Kelly McCann is a hematologist oncologist who practices in Santa Monica and Beverly Hills. She is board certified in internal medicine, hematology and medical oncology. Her clinical interests include breast cancer, gynecologic malignancies and palliative care.
Dr. McCann is also a scientific researcher, who is a member of Dr. Dennis Slamon’s Translational Oncology Research Laboratory. Her basic science research is focused on the genetic and molecular biology of cancer, with the goal of developing new targeted anti-cancer therapies.
Dr. McCann received both her medical degree and her PhD in cancer biology from Stanford University as part of their Medical Scientist Training Program. She completed her internal medicine residency at Oregon Health and Science University, and her fellowship in hematology and oncology at UCLA, after which she joined the faculty in the Breast Cancer Research Group. She earned her undergraduate degree in biomedical engineering from Rice University in Houston.
